Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Queensland Health
Cantor Fitzgerald
Federal Trade Commission

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,395,767

« Back to Dashboard

Summary for Patent: 6,395,767

Title: Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Abstract:Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula ##STR1## where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); n is 0 or 1; X is H or CN; and wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor *or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.
Inventor(s): Robl; Jeffrey A. (Newtown, PA), Sulsky; Richard B. (West Trenton, NJ), Augeri; David J. (Princeton, NJ), Magnin; David R. (Hamilton, NJ), Hamann; Lawrence G. (Cherry Hill, NJ), Betebenner; David A. (Lawrenceville, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/788,173
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

No matches for this query

International Patent Family for Patent: 6,395,767

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Peru07712002► Subscribe
New Zealand520821► Subscribe
Norway2012009► Subscribe
Norway2010006► Subscribe
Norway324227► Subscribe
Norway20024295► Subscribe
Netherlands300436► Subscribe
MexicoPA02008837► Subscribe
Luxembourg91985► Subscribe
Luxembourg91650► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus